Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study

BACKGROUND: Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with H...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Main Authors: About, Frédégonde, Oudot-Mellakh, Tiphaine, Niay, Jonathan, Rabiéga, Pascaline, Pedergnana, Vincent, Duffy, Darragh, Sultanik, Philippe, Cagnot, Carole, Carrat, Fabrice, Marcellin, Patrick, Zoulim, Fabien, Larrey, Dominique, Hézode, Christophe, Fontaine, Hélène, Bronowicki, Jean-Pierre, Pol, Stanislas, Albert, Matthew L., Theodorou, Ioannis, Cobat, Aurélie, Abel, Laurent
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2015
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4682920/
https://ncbi.nlm.nih.gov/pubmed/26670100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0145105
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares